Olmedo-Ocampo R, Guido-Guerra RE

Idioma: Español
Referencias bibliográficas: 12
Paginas: 191-193
Archivo PDF: 160.58 Kb.

RESUMEN

El riñón participa en el metabolismo y depuración de múltiples fármacos, por lo que para definir la analgesia perioperatoria en pacientes nefrópatas, se debe considerar la tasa de filtrado glomerular (TFG) y el riesgo de lesión renal aguda. Dado que en esta población el uso de AINEs y opioides se vuelve limitado, siempre se recomendará privilegiar bloqueos neuroaxiales o periféricos, el uso de analgesia multimodal y de gabapentinoides con los respectivos ajustes de dosis.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Tawfic Q, Bellingham G. Postoperative pain management in patients with chronic kidney disease. Journal of Anaesthesiology Clinical Pharmacology. 2015;31:6.

2. Summary of Recommendation Statements. Kidney International Supplements. 2013;3:5-14.

3. Summary of Recommendation Statements. Kidney International Supplements. 2012;2:8-12.

4. Ungprasert P, Cheungpasitporn W, Crowson C, Matteson E. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. European Journal of Internal Medicine. 2015;26:285-291.

5. Bell S, Rennie T, Marwick CA, Davey P. Effects of peri‐operative nonsteroidal anti‐inflammatory drugs on post‐operative kidney function for adults with normal kidney function. Cochrane Database of Systematic Reviews. 2018;11.

6. Solomon D, Husni M, Libby P, Yeomans N, Lincoff A, Lüscher T, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. The American Journal of Medicine. 2017;130:1415-1422.e4.

7. Koncicki HM, Unruh M, Schell JO. In practice pain management in CKD: a Guide for Nephrology Providers. Am J Kidney Dis. 2016. doi: 10.1053/j.ajkd.2016.08.039.

8. Barakzoy A, Moss A. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. Journal of the American Society of Nephrology. 2006;17:3198-3203.

9. Davison S, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Seminars in Dialysis. 2014;27:188-204.

10. Raouf M, Atkinson T, Crumb M, Fudin J. Rational dosing of gabapentin and pregabalin in chronic kidney disease. Journal of Pain Research. 2017;10:275-278.

11. Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J. Acute pain management: scientific evidence, 2015. Medical Journal of Australia. 2016;204:315-317.

12. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29:1970-1978.